Should I Buy Valeant Stock After Q4 2015 Earnings?

Valeant not only missed expectations in its Q4 2015 earnings report, but also provided a bleak outlook for 2016. The drug maker has dealt with countless scandals over the past six months, which has made the Valeant stock price plunge over 78% from its 52-week high of $263.81. Now, some on Wall Street are saying that this is a great time to buy VRX at a discount. But here's what you really need to know... Tags: NYSE: VRX , Valeant Pharmaceuticals Q4 2015 earnings , Valeant Q4 2015 earnings , Valeant stock , Valeant stock price , Valeant stock price 2016 , VRX stock , VRX stock price To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2016 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Should I Buy Valeant Stock After Q4 2015 Earnings? appeared first on Money Morning - We Make Investing Profitable .